TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05500001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Patients by Family Education in Psychotic Illness Group
Description: Psychoeducation for families supporting young adults with psychosis.
Study: NCT05179369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care with Well-Mama Intervention
Description: The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
Study: NCT04911270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Decision Support Tool Intervention Group
Description: Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC

Intervention type: OTHER
Group type: OTHER
Intervention: Matched Historical Controls
Description: Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
Study: NCT06420661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE for T1D
Description: school-partnered collaborative care model

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: routine diabetes care with optional monthly insulin dose adjustment
Study: NCT06237218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COTID program
Description: COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
Study: NCT05059236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788, Nubeqa)
Description: 300 mg per tablet, oral administration with food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADT
Description: LHRH agonist/antagonist or orchiectomy
Study: NCT04192435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 100mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.
Study: NCT06007898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent self-help psychological resource
Description: A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
Study: NCT05817942

Intervention type: DRUG
Intervention: Filgotinib
Description: Jyseleca
Study: NCT05046171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing
Description: A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Subjects receive a written pamphlet about deprescribing.
Study: NCT05339087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat Oral Tablet
Description: Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
Study: NCT03891849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Injection
Description: Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
Study: NCT06575738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable semaglutide
Description: Subcutaneous weekly injectable semaglutide

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual postoperative care
Description: Usual postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual postoperative care
Description: Usual postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
Study: NCT06428500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3046
Description: QTX3046 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3046
Description: QTX3046 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3046
Description: QTX3046 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTX3046
Description: QTX3046 will be administered at protocol defined dose.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at protocol defined dose.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at protocol defined dose.
Study: NCT05827250

Intervention type: DEVICE
Intervention: imPulse Tor
Description: The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings.
Study: NCT04687150

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colored water
Description: Colored water (placebo)
Study: NCT04936243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOLLOW UP VISIT-TELEMEDICINE
Description: Routine follow up care conducted remotely with video-conferencing tools

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOLLOW UP VISIT-FACE TO FACE
Description: Routine follow up care conducted in person
Study: NCT05466812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sr-89
Description: 1. strontium-89 chloride treatment~2. periodical evaluation and follow-up
Study: NCT06653426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate (NaBu)
Description: Participants will self-administer Sodium Butyrate (NaBu) daily for 12 weeks. The study aims to evaluate the effect of NaBu on menstrual symptoms by comparing symptom severity before and during the intervention. Participants will maintain an electronic diary (eDiary) to record their daily symptom severity, which will be used to assess changes over time. Regular follow-ups will be conducted to monitor progress and address any side effects or concerns.
Study: NCT05229926

Intervention type: DEVICE
Intervention: CareCube
Description: modular, disposable, negative pressure, isolation patient care system
Study: NCT06589258

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Assessing maternal and lactational plasma CBD uptake at different stages of breastfeeding
Description: Determination of delta 9-tetrahydrocannabinol (THC) and its metabolites , and of cannabidiol and its metabolites in blood and breasts-milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Realization of THC/CBD ratio; qualitative research in mother's and breast-fed child's urine for the presence of cannabinoids (THC, CBD and its metabolites).
Study: NCT06593093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a bundled intervention
Description: a bundled intervention, including peer support, buprenorphine (ranging from 4mg-24mg, oral, daily), telehealth, and community-based addiction programs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a bundled intervention
Description: a bundled intervention, including peer support, buprenorphine (ranging from 4mg-24mg, oral, daily), telehealth, and community-based addiction programs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: participants will not be intervened with this bundled treatment, but continue the usual care that has been established at UAB ED.
Study: NCT05146284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Tablet
Study: NCT06660264

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist Personalized Medication Review (PMR)
Description: Pharmacist-provided review of current medications and assessment of potential medication related problems.

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist Personalized Medication Review (PMR)
Description: Pharmacist-provided review of current medications and assessment of potential medication related problems.

Intervention type: OTHER
Group type: OTHER
Intervention: Discussion of Pharmacogenomic results during the PMR
Description: Return of pharmacogenomic results and discussion of impact on medications.
Study: NCT06678438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided brachial plexus block
Description: The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haematoma Block
Description: Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices
Study: NCT06618859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
Study: NCT04256486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Model Diabetes Self-Management Education and Support
Description: Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Model Diabetes Self-Management Education and Support
Description: Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
Study: NCT05323591

Intervention type: DRUG
Intervention: Filgotinib
Description: Tablets are administered in accordance with the product label
Study: NCT06629506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroMatrix® Flex
Description: MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroMatrix® UBM Particulate
Description: MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytal® Wound Matrix 2-Layer
Description: Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
Study: NCT06691165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low oxygen therapy (LOT)
Description: Participants will breathe variable concentrations of inspired oxygen, carbon dioxide, and nitrogen. The concentrations will be adjusted on a breath-by-breath basis to maintain end-tidal targets.~Each daily session of the intervention will consist of forty 1-minute intervals. Each 1-minute interval will consist of 40 seconds of hypercapnic hypoxia, increasing the partial pressure of end-tidal carbon dioxide by +4 mmHg and decreasing the partial pressure of end-tidal oxygen to 45 mmHg, followed by 20 seconds in simulated room air to return to baseline carbon dioxide and oxygen levels.
Study: NCT05393713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 Monoclonal Antibody IMC-001
Description: Given intra-lymphatically via DoseConnect device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: Undergo punch biopsy
Study: NCT06693310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: de-escalation or discontinuation of therapy
Description: De-escalation of therapy, defined as a step-down from maintenance with advanced therapy (biologic or synthetic small molecule) to oral aminosalicylate-based therapy or complete discontinuation of therapy if they are allergic or intolerant to aminosalicylate-based therapy. If patients are receiving immunomodulator or oral aminosalicylate maintenance therapy, they will be de-escalated to complete discontinuation of therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuation of current therapy
Description: continuation of current maintenance medical therapy for ulcerative colitis
Study: NCT06715540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 1
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 2
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 3
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 4
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 5
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 6
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, pre-specified therapeautic dose X
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, pre-specified therapeautic dose X
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, pre-specified therapeautic dose X
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, pre-specified therapeautic dose Y
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Study: NCT06717867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Description: Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.
Study: NCT06724978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-740792
Description: Participants will receive S-740792 as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-740792
Description: Participants will receive S-740792 as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive midazolam as a syrup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as an oral suspension.
Study: NCT06727110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PILP Cement
Description: PILP cement liner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PILP Conditioner
Description: PILP solution.
Study: NCT06724016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM16390
Description: HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
Study: NCT06734520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: super-transplantation in 3 severe β -thalassemia pediatric patients.
Description: Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
Study: NCT06735703

Intervention type: DRUG
Intervention: To provide ampicillin sulbactam to pregnant women with premature rupture of membrane
Description: To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation
Study: NCT06735261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block using 2% lidocaine
Description: A hollow-stem swab soaked in viscous Xylocaine is inserted into the patient's nasal cavity (one swab per nostril) until it stops. 1.5ml Lidocaine 20% (20mg/ml) is injected into each swab using a 5ml syringe and a pink trocar. Both swabs are left in place for 10 min.
Study: NCT06735963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meta Quest 3 Virtual Reality
Description: Immersive virtual reality Meta Quest 3 device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Traditional exercise program for knee OA patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Traditional exercise program for knee OA patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)
Study: NCT06735508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA Neoantigen Vaccine
Description: mRNA Neoantigen Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab is a programmed death-ligand 1 antibody.
Study: NCT06734468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Management
Description: Each subject will receive a personalized intervention plan, comprised of:~1. An individualized exercise plan guided by a mobile phone app.~2. Healthy diet and nutrition recommendations.~3. Theriome metabolomics testing and individualized recommendations that include dietary supplements.~4. Guidance on healthy sleep patterns, stress management, and maximizing social engagement, as appropriate.
Study: NCT06735820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Combination therapy of APG-115 and Selumetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Combination therapy of APG-115 and Selumetinib
Study: NCT06736002

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution